FMS - Fresenius Medical Care AG & Co. KGaA

NYSE - Nasdaq Real Time Price. Currency in USD
49.76
+0.43 (+0.87%)
As of 11:00AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close49.33
Open49.72
Bid49.76 x 1200
Ask49.78 x 1300
Day's Range49.62 - 49.80
52 Week Range44.88 - 57.94
Volume21,493
Avg. Volume130,326
Market Cap30.586B
Beta0.98
PE Ratio (TTM)20.99
EPS (TTM)2.37
Earnings DateN/A
Forward Dividend & Yield0.63 (1.29%)
Ex-Dividend Date2018-05-21
1y Target Est61.78
Trade prices are not sourced from all markets
  • The Wall Street Journal18 days ago

    [$$] Fresenius Medical Sells Sound Inpatient Physicians for $2.15 Billion

    Fresenius Medical Care AG said it completed the divestment of Sound Inpatient Physicians Holdings, selling the business to an investment consortium led by Summit Partners. The German company, which provides dialysis services, said the divestment will bolster its net income by about $752 million.

  • Here's Why You Should Steer Clear of Fresenius Medical Now
    Zacks18 days ago

    Here's Why You Should Steer Clear of Fresenius Medical Now

    Soft segmental performance and a downbeat revenue guidance reflect Fresenius Medical's (FMS) weaknesses.

  • Is Fresenius Medical Care AG & Co KGaA (ETR:FME) A Buy At Its Current PE Ratio?
    Simply Wall St.25 days ago

    Is Fresenius Medical Care AG & Co KGaA (ETR:FME) A Buy At Its Current PE Ratio?

    The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and want to better understand how you canRead More...

  • Reuterslast month

    FMC takes stake in Humacyte in bet on bioengineered blood vessel

    Germany's Fresenius Medical Care (FMC) (FMEG.DE) has agreed to take a $150 million (112.3 million pounds) stake in U.S. tissue engineering firm Humacyte Inc. and will become the exclusive distributor of the company's bioengineered blood vessels once they win approval. The world's largest provider of kidney dialysis, FMC is banking on the alliance to lead to better ways of accessing patients' blood vessels, a delicate medical procedure that is part of providing life-saving dialysis, the company said in a statement on Monday. FMC will take a 19 percent stake in the privately held company.

  • Durham’s Humacyte lands $150M from Fresenius Medical Care
    American City Business Journalslast month

    Durham’s Humacyte lands $150M from Fresenius Medical Care

    Durham-based Humacyte has landed a $150 million equity investment from Fresenius Medical Care. According to the companies, the investment will see Fresenius (NYSE: FMS) take a 19 percent fully diluted ownership stake in Humacyte and obtain the exclusive global rights to commercialize Humacyte’s human acellular vessel Humacyl upon approval by certain health authorities.  “Humacyte is at this true inflection point in the development of our blood vessel,” says Humacyte Chief Medical Officer Dr. Jeff Lawson.

  • PR Newswirelast month

    Fresenius Medical Care and Humacyte announce strategic global partnership supported by a $150M equity investment

    BOSTON, June 11, 2018 /PRNewswire/ -- Fresenius Medical Care, the world's largest provider of dialysis products and services, and Humacyte, Inc., a medical research, discovery and development company, today announced a strategic, global partnership and a $150M USD equity investment. This agreement has the potential to make Humacyte's investigational human acellular vessel, HUMACYL®, available to more patients worldwide following approval of the product. HUMACYL is currently being investigated for vascular access for hemodialysis and may prove more effective than current synthetic grafts and fistula.

  • Moody'slast month

    Ironman Merger Sub, LLC -- Moody's assigns B1 CFR to Ironman Merger Sub, LLC (aka Sound Inpatient Physician Holdings, LLC)

    Moody's Investors Service (Moody's) assigned a B1 Corporate Family Rating (CFR) and B1-PD Probability of Default Rating to Ironman Merger Sub, LLC. Ironman Merger Sub, LLC will become Sound Inpatient Physician Holdings, LLC ("Sound") immediately following the $2.2 billion acquisition of the company. Sound will be acquired by Summit Partners and OptumHealth Holdings, LLC ("OptumHealth") from Fresenius Medical Care AG & Co. KGaA (Baa3 stable). OptumHealth is owned by health insurance company UnitedHealth Group, Inc. (A3 stable).

  • Why Cara Therapeutics Shares Jumped 10% Today
    Motley Fool2 months ago

    Why Cara Therapeutics Shares Jumped 10% Today

    Investor optimism continues following an important licensing deal earlier in the week.

  • Does This New Partnership Make Cara Therapeutics Stock a Buy Now?
    Motley Fool2 months ago

    Does This New Partnership Make Cara Therapeutics Stock a Buy Now?

    A new deal with a major dialysis provider could propel Korsuva much further than expected.

  • Benzinga2 months ago

    Cara Therapeutics Shares Jump On Licensing Deal For Pruritis Treatment

    Cara said it has licensed worldwide rights — except in the U.S., Japan and South Korea — to commercialize Korsuva injection with VFMCRP, a joint venture between Vifor Pharma and Fresenius Medical Care AG & Co. (ADR) (NYSE: FMS). The deal provides for a $50-million upfront cash payment to Cara and an equity investment of $20 million via share sales at $17 apiece.

  • Here's Why You Should Sell Fresenius Medical (FMS) Stock Now
    Zacks2 months ago

    Here's Why You Should Sell Fresenius Medical (FMS) Stock Now

    A rapidly changing healthcare environment in the United States, sluggish Q1 and competition in the niche markets are major headwinds for Fresenius Medical (FMS).

  • NxStage Keeps Losing Money as Key Deadline Grows Nearer
    Motley Fool2 months ago

    NxStage Keeps Losing Money as Key Deadline Grows Nearer

    Find out why concerns about the dialysis specialist's merger are getting worse.

  • Are Fresenius Medical Care AG & Co KGaA’s (ETR:FME) Interest Costs Too High?
    Simply Wall St.2 months ago

    Are Fresenius Medical Care AG & Co KGaA’s (ETR:FME) Interest Costs Too High?

    Investors pursuing a solid, dependable stock investment can often be led to Fresenius Medical Care AG & Co KGaA (XTRA:FME), a large-cap worth €26.04B. Risk-averse investors who are attracted toRead More...

  • Fresenius Medical (FMS) Misses on Q1 Earnings, Lowers View
    Zacks2 months ago

    Fresenius Medical (FMS) Misses on Q1 Earnings, Lowers View

    Lackluster performance in North America and foreign exchange headwinds mar Fresenius Medical's (FMS) bottom line in Q1.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of FME.DE earnings conference call or presentation 3-May-18 1:30pm GMT

    Q1 2018 Fresenius Medical Care AG & Co KGaA Earnings Call

  • Here's Why Akorn Inc Fell as Much as 16.4% Today
    Motley Fool2 months ago

    Here's Why Akorn Inc Fell as Much as 16.4% Today

    Investors received new details explaining why Fresenius dropped its acquisition. They aren't good.

  • PR Newswire3 months ago

    RenalSense Announces Distribution Agreement With Fresenius Medical Care

    JERUSALEM , April 30, 2018 /PRNewswire/ -- RenalSense® has entered into an agreement with Fresenius Medical Care (Bad Homburg) for distribution of its Clarity RMS® critical care urine monitoring system ...

  • The Zacks Analyst Blog Highlights: ArcelorMittal, Fresenius Medical Care AG, Orion Engineered Carbons S.A., Royal Dutch Shell and Globant S.A.
    Zacks3 months ago

    The Zacks Analyst Blog Highlights: ArcelorMittal, Fresenius Medical Care AG, Orion Engineered Carbons S.A., Royal Dutch Shell and Globant S.A.

    The Zacks Analyst Blog Highlights: ArcelorMittal, Fresenius Medical Care AG, Orion Engineered Carbons S.A., Royal Dutch Shell and Globant S.A.

  • Why Akorn, Inc.'s Stock Is Up Big Today
    Motley Fool3 months ago

    Why Akorn, Inc.'s Stock Is Up Big Today

    The drama continues.

  • ECB Sticks to Accommodative Monetary Stance: 5 Top Picks
    Zacks3 months ago

    ECB Sticks to Accommodative Monetary Stance: 5 Top Picks

    The ECB kept its main refinancing rate, and rates on marginal lending facility and deposit facility at unchanged at 0%, 0.258% and -0.4%, respectively.

  • Why Chicago Bridge & Iron, Akorn, and Flotek Industries Slumped Today
    Motley Fool3 months ago

    Why Chicago Bridge & Iron, Akorn, and Flotek Industries Slumped Today

    Find out why these stocks led the market lower.

  • Reuters3 months ago

    Jilted Akorn sues Fresenius over deal termination

    U.S. generic drugmaker Akorn (AKRX.O) is taking former suitor Fresenius (FREG.DE) to court after the German healthcare group cancelled their $4.75 billion (3.4 billion pounds) takeover agreement. Akorn shares lost more than a third of their value on Monday, the day after Fresenius pulled out of a deal first announced last April. The German company cited evidence of misconduct in Akorn's reporting of drug development data to U.S. healthcare regulators.

  • Reuters3 months ago

    Jilted Akorn sues Fresenius over deal termination

    U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group cancelled their $4.75 billion takeover agreement. Akorn shares lost more than a third of their value on Monday, the day after Fresenius pulled out of a deal first announced last April. The German company cited evidence of misconduct in Akorn's reporting of drug development data to U.S. healthcare regulators.

  • TheStreet.com3 months ago

    Akorn's Stock Crashes as Germany's Fresenius Ends Takeover Amid Data Allegations

    dropped its planned $5 billion takeover of the generic drugmaker after a probe into possible data breaches by the U.S. Food & Drug Administration. Fresenius said it found "material" breaches of FDA1 data integrity rules as part of its own investigation into allegations levelled against the Lake Forest, Ill.-based Akorn earlier this year and offered to delay its proposed takeover if the group could supply information that would allow Fresenius to reconsider. The Germany company said Akorn declined that offer.

  • Reuters3 months ago

    Fresenius shares gain after it ditches Akorn takeover

    Shares in healthcare group Fresenius jumped as much as 3.9 percent after it pulled out of the $4.75 billion acquisition of Akorn, with analysts saying it was extricating itself from taking on an underperforming business. Germany's Fresenius on Sunday cited evidence of misconduct in the target's reporting of drug development data to U.S. healthcare regulators, but analysts pointed to investor relief because Akorn's business had deteriorated. "Investors will likely be pleased that the merger agreement has been terminated, given the substantial decline in Akorn’s operating performance since the agreement was signed last April," said Berenberg analyst Tom Jones.